Hepatitis D is a viral liver infection caused by the hepatitis D virus (HDV), and it holds a strange distinction in medicine: it cannot infect a person on its own. HDV is entirely dependent on the hepatitis B virus (HBV) to supply the outer protein coat it needs to enter liver cells and spread, making it the only known human virus that is an obligate satellite of another virus. This dependence means hepatitis D only affects people who already carry hepatitis B, but when both viruses are present, the combination produces the most severe form of chronic viral hepatitis known.
Why Hepatitis D Cannot Exist Without Hepatitis B
HDV is remarkably minimal. Its genome is a tiny circle of single-stranded RNA, one of the smallest genomes of any animal virus, encoding just one protein in two forms (the small and large delta antigens).1PubMed Central. Structure and replication of the genome of the hepatitis delta virus With so little genetic material, HDV cannot build its own outer shell. Instead, it hijacks the surface proteins of hepatitis B to assemble infectious particles. The core of the virus particle is pure HDV, a ribonucleoprotein complex containing the delta antigen wrapped around the circular RNA, but the envelope coating those particles comes entirely from HBV.2PubMed Central. Support of the infectivity of hepatitis delta virus particles by the envelope proteins of different genotypes of hepatitis B virus Without that borrowed coat, HDV cannot get into liver cells and cannot produce new virions to infect other cells. This is why every person with hepatitis D is, by definition, also infected with hepatitis B.
Two Routes of Infection and Why the Distinction Matters
There are two fundamentally different ways a person acquires hepatitis D, and the clinical consequences are dramatically different depending on which route is involved.
In coinfection, a person is exposed to both HBV and HDV at the same time, typically through the same contaminated blood or body-fluid contact. The immune system fights both viruses simultaneously, and the outcome is usually favorable. Roughly 95% of people with acute coinfection clear both viruses, and chronic infection develops in only about 2% of cases.3JAMA. Hepatitis D: A Review 4PubMed. Clinical features of hepatitis D The acute illness itself looks similar to ordinary hepatitis B in terms of symptoms and liver-function test results; studies comparing the two groups have found no significant differences in the clinical course or blood test patterns during the acute phase.5PubMed. Hepatitis B virus replication in hepatitis B and D coinfection 6PubMed. Hepatitis B virus replication in acute hepatitis B, acute hepatitis B virus-hepatitis delta virus coinfection and acute hepatitis delta superinfection
Superinfection is the more dangerous scenario. Here, a person already chronically infected with hepatitis B is later exposed to HDV. Because the immune system has already settled into a chronic relationship with HBV and cannot clear it, HDV finds a welcoming environment. Over 90% of superinfections become chronic.7JAMA. Hepatitis D: A Review This is the route responsible for most of the world’s chronic hepatitis D cases and the severe liver disease that comes with them.
Who Is at Risk and Where Hepatitis D Is Found
Because HDV can only infect people who carry hepatitis B surface antigen (HBsAg), the global footprint of hepatitis D is nested inside the larger hepatitis B epidemic but concentrated in certain regions. A large systematic review found the highest prevalence among HBsAg-positive people in Mongolia, the Republic of Moldova, and countries across western and central Africa.8PubMed Central. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis Within Africa, Cameroon, Gabon, and Nigeria stand out for particularly high rates.9PubMed Central. Hepatitis D epidemiology and access to diagnostic testing among healthcare providers in Africa: A multi-country survey
Certain groups carry elevated risk regardless of geography. People who inject drugs, those on long-term hemodialysis, men who have sex with men, sex workers, and people co-infected with HIV or hepatitis C all show higher rates of HDV when they are already HBsAg-positive.10PubMed Central. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis Transmission follows the same routes as hepatitis B: blood-to-blood contact, sexual contact, and vertical transmission from mother to child are all possible.
The Liver Damage Is Worse Than Hepatitis B Alone
Chronic hepatitis D is recognized as the most aggressive form of chronic viral hepatitis.11PubMed. Prediction of Hepatocellular Carcinoma and Liver-related Events in Anti-hepatitis D Virus-positive Individuals The virus does not directly kill liver cells the way some other pathogens do. Instead, the damage is largely driven by the immune system’s inflammatory response. HDV interferes with the body’s interferon signaling, activates delta-specific immune cells, and triggers pathways involving tumor necrosis factor and other inflammatory molecules. This cascade produces severe, ongoing liver inflammation. At the same time, HDV infection is associated with increased expression of factors that promote cell survival and growth, a combination that helps explain why affected livers develop cirrhosis faster and have a higher risk of progressing to liver cancer.12PubMed Central. Life cycle and pathogenesis of hepatitis D virus: A review
The numbers bear this out. Among patients who already had HBV-related cirrhosis, those co-infected with HDV developed liver cancer at roughly three times the rate of those with hepatitis B alone. After five years, about 20% of co-infected cirrhosis patients had developed liver cancer compared to roughly 4% of those with HBV alone.13PubMed. Hepatitis D Virus Infection Markedly Increases the Risk of Hepatocellular Carcinoma in Patients With Viral B Cirrhosis A separate study of patients on hepatitis B antiviral therapy found that active HDV replication, meaning detectable virus in the blood, was one of the strongest factors predicting liver cancer, with a five-year cancer rate of about 22% in those with active HDV compared to about 7% in those without.14Scientific Reports. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues
A Massively Underdiagnosed Infection
Despite the severity of hepatitis D, a startling number of people who carry it have never been tested. The diagnosis starts with a simple antibody blood test (anti-HDV) in anyone who is HBsAg-positive, but this first step is skipped far too often. A large European cohort study found that only about half of HBsAg-positive patients had been screened for HDV, with rates varying wildly across centers, from as low as 8% to as high as 88%.15PubMed. HERACLIS-HDV cohort for the factors of underdiagnosis and prevalence of hepatitis D virus infection in HBsAg-positive patients In Africa, the diagnostic gap is even wider, with limited access to testing infrastructure compounding the problem.16PubMed Central. Hepatitis D epidemiology and access to diagnostic testing among healthcare providers in Africa: A multi-country survey
Even when antibody screening is done, the diagnostic process often stalls. A positive anti-HDV test tells you the person has been exposed but does not confirm active, ongoing infection. For that, you need an HDV RNA test, which directly detects the virus circulating in the blood. These RNA assays perform well, with high sensitivity and specificity across multiple studies.17PubMed Central. Performance of Hepatitis Delta Virus RNA Testing for the Diagnosis of Active HDV Infection: Systematic Review and Meta-analysis But antibody levels alone are unreliable markers of active infection. Researchers have found only moderate agreement between antibody patterns and actual virus presence in the blood, meaning relying on antibodies alone would miss a significant number of actively infected patients.18PubMed. Diagnostic value of anti-hepatitis D virus (HDV) antibodies revisited
This matters more now than it used to, because effective treatments have recently become available. When there was little to offer patients, missing a diagnosis was tragic but therapeutically moot. Now that targeted drugs exist, every missed case represents a missed opportunity to intervene. Some experts have called for reflex testing, where a positive HBsAg result automatically triggers an HDV antibody test followed by RNA confirmation, to close this gap.19Liver International Communications. Bridging the Diagnostic Gap in Chronic Hepatitis D: Implementing Reflex Testing and Standardized HDV RNA Assessment in the Therapeutic Era
Treatment Before Bulevirtide
For decades, the only treatment option for chronic hepatitis D was pegylated interferon, an injectable immune-boosting drug given weekly for at least a year. The results were modest at best. A meta-analysis of 13 studies found that only about 29% of patients achieved undetectable virus levels after treatment, and about a third showed normalized liver enzymes.20PubMed. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis Virtually no one cleared the hepatitis B surface antigen, meaning a functional cure of the underlying HBV was almost never achieved.21PubMed. Interferon-based treatment of chronic hepatitis D
The standard HBV antivirals like entecavir and tenofovir, which work well against hepatitis B on their own, do not directly suppress HDV. Adding entecavir to interferon did not improve the rate of HDV clearance beyond what interferon achieved alone.22PubMed Central. Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial This failure makes biological sense: those drugs target the HBV replication machinery, but HDV replicates using a completely different strategy, relying on host cell enzymes rather than its own. Suppressing HBV DNA does not stop HDV RNA from being produced.
Bulevirtide Changed the Landscape
The approval of bulevirtide (sold as Hepcludex) marked a turning point. Rather than attacking the virus inside the cell, bulevirtide works at the cell’s front door. It is a synthetic peptide that binds to NTCP, the receptor on liver cells that both HBV and HDV use to get inside. By occupying that receptor, bulevirtide blocks new virions from entering healthy liver cells.23PubMed Central. Bulevirtide (Hepcludex): Mechanism and Pharmacology It does not kill cells that are already infected, but it starves the infection over time by preventing the virus from spreading to fresh cells.
In a phase 2 trial, patients receiving bulevirtide showed significant drops in HDV RNA levels over 24 weeks. At the highest tested dose, over three-quarters of patients achieved either undetectable virus or a major decline in viral load, compared to just 4% on a control drug.24The Lancet Infectious Diseases. Bulevirtide with or without tenofovir disoproxil fumarate in patients with chronic hepatitis delta (MYR202) The drug also normalizes liver enzymes, a sign that ongoing inflammation is being controlled. Its safety profile has been encouraging even at high doses over 48 weeks, and combining it with interferon appears to produce stronger effects on both HDV and HBV markers than either drug alone.25PubMed Central. Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect
There is an important caveat. In the trial data so far, stopping bulevirtide led to a rebound in HDV RNA levels.26The Lancet Infectious Diseases. Bulevirtide with or without tenofovir disoproxil fumarate in patients with chronic hepatitis delta (MYR202) This suggests that long-term, possibly indefinite, treatment may be necessary for many patients, similar to how HBV antivirals work. The drug is administered as a daily subcutaneous injection, which is a practical consideration for people who will be on it for years.
Other Drugs in the Pipeline
A second therapeutic approach targets prenylation, a chemical modification that the large delta antigen needs in order to interact with the HBV envelope and assemble new virus particles. Without this step, the virus can replicate its RNA inside the cell but cannot package itself into infectious particles to spread. Lonafarnib, a prenylation inhibitor originally developed as a cancer drug, has been tested in hepatitis D. In a proof-of-concept trial, patients receiving lonafarnib for 28 days showed significant drops in virus levels compared to placebo, with higher drug doses producing stronger effects. The virus’s half-life during treatment was estimated at about 1.6 days, meaning the drug was clearing circulating virus fairly rapidly.27PubMed Central. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial 28The Lancet Infectious Diseases. Prenylation inhibitor lonafarnib for chronic delta hepatitis: a phase 2, randomised, double-blind, placebo-controlled trial
Lonafarnib works by a completely different mechanism than bulevirtide. One blocks the virus from entering cells; the other blocks it from leaving. In principle, combining the two could squeeze the virus from both ends. Researchers are also investigating the molecular details of how the prenylation motif at the end of the large delta antigen contributes to virus assembly, which could point toward even more precise drug targets.29JHEP Reports. Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly
Living With Chronic Hepatitis D
The impact of hepatitis D extends beyond liver function tests. Patients with chronic hepatitis D report significantly more worry about their disease than those with hepatitis B alone, and they experience greater impairment in daily activities.30PubMed Central. Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B Qualitative research has found that the disease affects emotional wellbeing, physical functioning, social participation, household tasks, and the ability to work.31PubMed Central. Exploring the patient experience of chronic hepatitis D (CHD) and assessment of content validity of the Hepatitis Quality of Life Questionnaire and (HQLQv2) and the Fatigue Severity Scale (FSS) Fatigue is a common complaint, and the psychological burden of carrying what patients often perceive as a rare, poorly understood condition compounds the physical symptoms.
For patients who progress to end-stage liver disease, transplantation remains an option, and the outcomes are reassuring. A U.S. study using national transplant registry data found that post-transplant survival for hepatitis D patients was essentially identical to that for hepatitis B patients without HDV. One-year, five-year, and ten-year survival rates were about 93%, 78%, and 69% in HDV patients, closely matching the HBV-only group.32Transplantation Direct. Liver Transplantation for Hepatitis D Virus in the United States: A UNOS Study on Outcomes in the MELD Era This parity is partly because the combination of hepatitis B immunoglobulin and antiviral drugs given after transplant effectively prevents HBV recurrence, and without HBV, HDV cannot re-establish itself.
Genotype Variation Around the World
HDV is not a single monolithic virus. Eight genotypes have been described, and they cluster geographically. Genotype 1 is the most widespread, dominating in Europe, the Middle East, North America, and parts of Africa. Genotype 2 is the most common form in Asia. Genotype 3 is concentrated in South America, particularly the Amazon basin. The remaining genotypes, sometimes grouped together as “African genotypes,” are found predominantly in sub-Saharan Africa.33Hepatitis Monthly. Global Distribution of Hepatitis D Virus Genotypes: A Systematic Review
These genotype differences are not just academic curiosities. They influence how the virus behaves clinically and how patients respond to treatment.34PubMed Central. Global Distribution and Natural Recombination of Hepatitis D Virus: Implication of Kyrgyzstan Emerging HDVs in the Clinical Outcomes Genotype 3, for instance, has been associated with particularly severe fulminant hepatitis outbreaks in South America. Because most clinical trials have been conducted in populations where genotype 1 predominates, how well the new drugs work against other genotypes remains an open question that global rollout will eventually need to address.
HDV’s Relatives in the Animal Kingdom
One of the more surprising discoveries in recent years is that HDV is not unique to humans. Viruses closely related to HDV have been found in an unexpectedly wide range of animals. Researchers identified a deltavirus in boa constrictors that shares the same basic structure and coding strategy as the human virus but is only about 37% identical in its delta antigen protein. The snake virus was detected in brain, blood, and liver tissue, suggesting a much broader tissue range than human HDV. No accompanying hepatitis-B-like virus was found in the infected snakes, raising the possibility that animal deltaviruses may partner with entirely different helper viruses or even replicate without one.35PubMed Central. Identification of a Novel Deltavirus in Boa Constrictors
A deltavirus found in a South American rodent species reinforced this picture. The rodent virus lacked the prenylation motif that human HDV uses to interact with the hepatitis B envelope, and no hepadnavirus co-infection was detectable in any of the positive animals.36PubMed Central. Mammalian deltavirus without hepadnavirus coinfection in the neotropical rodent Proechimys semispinosus Even more striking, HDV-like circular RNAs have been detected in the genetic material of fish, amphibians, and even termites. Some of these carry self-cleaving RNA structures related to but distinct from those in human HDV, suggesting the deltavirus lineage may be ancient and far more diverse than anyone suspected when it was thought to be a quirk of human hepatitis B.37PubMed Central. Hepatitis delta virus-like circular RNAs from diverse metazoans encode conserved hammerhead ribozymes
These findings have reshaped how virologists think about HDV’s origins. Rather than evolving recently as a satellite of hepatitis B, deltaviruses may represent a very old class of RNA agents that have adapted to different helper viruses, or possibly to life without a helper, across the animal kingdom. The human virus’s exclusive dependence on HBV may be a relatively recent evolutionary arrangement rather than a fundamental feature of the deltavirus family.
How Discovery Shaped Understanding
The delta antigen was first described in 1977 by Mario Rizzetto and colleagues in Turin, Italy, who noticed a new antigen in the liver cell nuclei of certain hepatitis B patients that was immunologically distinct from any known HBV marker.38PubMed Central. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers It took nearly a decade of further work to characterize the circular RNA genome and recognize that this was not just a new marker of hepatitis B but an entirely separate virus piggybacking on it. The initial confusion was understandable: under immunofluorescence, the delta antigen looked similar to the hepatitis B core antigen, and only specific antisera could distinguish the two.
This history matters because it illustrates a pattern that persists today. Hepatitis D hides inside the shadow of hepatitis B. Clinicians who are not specifically looking for it will attribute a patient’s worsening liver disease to hepatitis B alone, especially in settings where HDV testing is not routine. The virus’s discovery required someone to notice that certain HBV patients were sicker than expected and to ask why. Four decades later, the same observational instinct is still the first step in diagnosis for many patients around the world.